ARCH Venture Partners, an American venture capital firm based in Chicago, led a $400m funding round in Mirador Therapeutics, a next-generation precision medicine company focused on immunology and inflammation, with participation from OrbiMed, Fairmount, Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments. “The I&I field is in need of better, novel therapeutics as well as new R&D approaches that target enriched patient populations for improved probability of success in the clinic. The Mirador team has an outstanding track record of success in precision immunology, and we are well on our way to building a company that will make a lasting impact on the lives of millions of patients suffering from a broad range of immune-mediated inflammatory and fibrotic diseases," Kristina Burow, ARCH Venture Partners Managing Director.